Bayer AG

339 articles with Bayer AG

• New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli Compared to Warfarin in Frail Patients with Non-Valvular Atrial Fibrillation

  5/24/2018

  The Janssen Pharmaceutical Companiesof Johnson & Johnson today announced new real-world data that showed frail patients with non-valvular atrial fibrillation (NVAF) experienced significantly fewer strokes and systemic emboli when treated with XARELTO® (rivaroxaban) over a two-year period compared to those taking warfarin.

• coreHEM Publishes Core Outcome Set for Hemophilia Clinical Trials; Prepares to Launch Next Phase of Work

  5/21/2018

  The coreHEM initiative has announced the publication of a core outcome set for clinical trials of gene therapy in hemophilia.

• Polyneuron Pharmaceuticals Completes CHF3.1 Million Seed Financing

  5/14/2018

  Polyneuron Pharmaceuticals AG, a developer of a new class of biodegradable glycopolymer treatments for autoimmune diseases, today announced the closing of a CHF3.1 million financing, following the receipt of a second tranche.

• 

  Higher Death Rate Forces Bayer to Stop Xofigo/Zytiga Combo Late-Stage Study Early

  12/1/2017

  An IDMC told Bayer that it should unblind its Phase III clinical trial in prostate cancer in order to further analyze an increased number of fractures and deaths.
• 

  Bayer's Former Head of Discovery Lands New CSO Gig at Shire

  12/1/2017

  There are some changes taking place in the C-suites at Shire.
• 

  Bayer Head of Discovery Exits as Drugmaker Combines Pharma R&D Unit

  11/30/2017

  The company's head of Development, Joerg Moeller, is taking the reins of the company's new R&D program.
• 

  Bayer Pharma Head Denies Pipeline Problem

  11/28/2017

  With the $63.5B takeover of Monsanto by Bayer taking longer than expected, and a key patent for Xarelto expiring in 2024, Bayer's execs are finding themselves defending their decisions.
• 

  Japan's PeptiDream Bags $1.11B+ R&D Pact With Bayer

  11/20/2017

  Peptidream has scored another billion dollar-plus agreement to develop peptide-based therapies aimed at the treatment multiple disease targets.

• Bayer Appoints Jennifer Brendel to Vice President, Head of U.S. Consumer Health Communications

  10/19/2017

  Bayer is proud to announce today the appointment of Jennifer Brendel to VP of Communications for the company's Consumer Health Division in the U.S.

• Bayer Appoints Brenda L. Raphael Senior Vice President and General Manager of Therapeutics Business Unit for Consumer Health

  10/18/2017

  Bayer today announced the appointment of Brenda L. Raphael as Senior VP and General Manager of the Therapeutics Business Unit of Consumer Health Commercial Operations North America, effective October 30, 2017.

• Versant Ventures-Bayer AG Partnership Represents Significant Milestone For Canada’s Biotech Sector And Innovation Economy

  12/12/2016

• As Monsanto Bid Stalls, Bayer AG Mulls Sale of $3 Billion Radiology Business

  6/20/2016

• Amid Shareholder Pressure, Bayer AG Makes Formal $62 Billion Bid for Monsanto

  5/24/2016

• Why Investors Should be Insulted Over Bayer AG's $40 Billion Offer for Monsanto

  5/19/2016

• Bayer AG Confirms Strategy Chief Werner Baumann as New CEO

  2/24/2016

• It’s Official — Bayer AG Now Made Up of Three Divisions

  9/23/2015

• Complaints for Bayer AG's Sterility Device Spike Nearly 1,400% in Three Years

  9/22/2015

• Bayer AG Adds Two Indications In China For Anticoagulant Xarelto

  5/5/2015

• Bayer AG To Educate Physicians And Veterinarians Around The Globe On Vector-Borne Diseases

  4/13/2015

• Bayer AG to Decide in Second Half on IPO or Spinoff for Plastics Unit

  2/26/2015